# NewAmsterdam Pharma Co N.V. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/NewAmsterdam Pharma Co N.V.). ## Overview NewAmsterdam Pharma Co N.V. is a clinical-stage biopharmaceutical company focused on developing oral therapies for cardiovascular disease, centered on obicetrapib and related formulations. The company is organized under Dutch law with operations and commercial planning tied to the United States and partnered European markets. ## Products & services • Obicetrapib oral LDL-C lowering therapy • Obicetrapib monotherapy tablets • Obicetrapib fixed-dose combination with ezetimibe • Licensed development rights for cardiovascular candidates • Commercial supply of drug product to Menarini - **Clinical-stage drug candidates** (0%) — Development-stage cardiovascular therapies, primarily obicetrapib and related formulations. - **Licensed intellectual property** (70%) — License rights granted to Menarini for commercialization in defined territories. - **Product supply** (30%) — Sale of obicetrapib tablets and active pharmaceutical ingredients to Menarini. - Obicetrapib oral LDL-C lowering therapy - Obicetrapib monotherapy tablets - Obicetrapib fixed-dose combination with ezetimibe - Licensed development rights for cardiovascular candidates - Commercial supply of drug product to Menarini ## Customers The company’s primary commercial counterparty is Menarini, which holds rights to commercialize obicetrapib in most European countries if approved. In the United States, the intended end customers are patients with high cardiovascular risk and residual elevated LDL-C, reached through physicians and specialty channels after regulatory approval. - **Menarini** (primary) — Buys license rights and product supply for commercialization in most European territories. - **Cardiovascular physicians** (primary) — Prescribe obicetrapib if approved for patients needing additional LDL-C lowering. - **Patients with residual LDL-C elevation** (primary) — End users targeted for oral therapy after standard lipid-lowering treatment. - **Specialty pharmacies and distributors** (secondary) — May handle distribution and fulfillment outside the U.S. or in selected regions. - **Future licensing partners** (emerging) — Potential collaborators for Japan, China, and other non-core markets. - Menarini as European licensee and commercial partner - Physicians treating high cardiovascular-risk patients - Specialty pharmacies and distributors, if used - Patients with residual elevated LDL-C - Potential future pharma partners in non-core territories ## Geography NewAmsterdam Pharma is incorporated in the Netherlands, with a registered office in Naarden and a U.S. agent subsidiary in Florida. Commercial rights for obicetrapib cover the majority of European countries through Menarini, while the company plans to pursue U.S. commercialization itself and evaluate partners for Japan, China, and other jurisdictions. - **United States** (50%) — Planned primary commercialization market and U.S. operating base - **Europe** (40%) — Majority of European countries covered by Menarini commercialization rights - **Rest of World** (10%) — Potential future partnering territories including Japan and China - Netherlands legal domicile and registered office - United States operating base and planned commercial launch market - Majority of European countries covered by Menarini rights - Potential expansion into Japan and China through partners - Cross-border development and supply chain coordination ## Strategy The company’s strategy is to advance obicetrapib through late-stage development, seek regulatory approval, and build commercialization capabilities in the United States. Outside the U.S., it relies on partnering, with Menarini serving as the key European commercialization partner and additional collaborations considered for other regions. - **Complete development and regulatory path for obicetrapib** (short-term) — Approval is required before the company can generate meaningful product sales. - **Build U.S. commercialization capability** (short-term) — The company intends to sell in the U.S. itself and needs sales and distribution infrastructure. - **Expand through partnerships outside core markets** (medium-term) — Partnering can extend reach while limiting the need to build local infrastructure everywhere. - **Broaden pipeline through licensing or acquisition** (medium-term) — Additional candidates can diversify the company beyond a single lead asset. - Advance obicetrapib through clinical development and approval - Build U.S. commercial infrastructure for launch readiness - Use Menarini to commercialize in most European markets - Pursue additional partners for Japan, China, and other regions - Evaluate acquisition or licensing of new product candidates ## Risks The company depends heavily on successful development and approval of a single lead asset, so clinical, regulatory, and commercialization setbacks could materially impair value. As a clinical-stage business with limited operating history, it also faces financing, execution, intellectual property, and partner-dependence risks typical of drug developers. - **Clinical development failure** [critical] — The company has no approved products and relies on obicetrapib's trial results. - **Regulatory approval delay or denial** [high] — Revenue depends on obtaining marketing authorization before commercialization. - **Commercial execution risk** [high] — The company has limited internal sales and marketing infrastructure. - **Partner concentration** [high] — Menarini is the key European commercialization counterparty and supply customer. - **Intellectual property and patent risk** [high] — Future value depends on protecting obicetrapib from generic or legal challenges. - **Financing and dilution risk** [high] — The company expects continued losses and may need external capital. - Single-asset concentration around obicetrapib - Clinical trial failure or delayed regulatory approval - Need to build U.S. sales and distribution capabilities - Dependence on Menarini and other third-party partners - Patent and IP challenges, including generic competition ## Accounting Revenue recognition is driven by a license agreement and supply arrangement with Menarini, including upfront consideration, deferred revenue, and variable cost-based pricing estimates. Because the company is clinical-stage, judgment around milestone probability, contract assets, and development cost contributions can materially affect reported revenue and period-to-period comparability. - **License and collaboration revenue recognition** — Affects timing of revenue recognition and deferred revenue balances - **Variable consideration in supply agreement** — Can cause quarter-to-quarter revenue variability - **Milestone and development contributions** — Can shift revenue between periods - **Clinical trial accruals and estimates** — Affects operating expense timing and comparability - License revenue recognized from Menarini upfront payment - Deferred revenue tied to ongoing R&D performance obligations - Variable consideration in Menarini supply pricing estimates - Milestone and development-cost contribution recognition judgment - U.S. GAAP estimates affect clinical-stage expense and revenue timing --- *Last updated: 2026-04-29T04:41:29.803505+00:00*